AI News Sentiment & Analysis
Immunome, Inc. (IMNM) — AI News Sentiment & Analysis
4 recent AI analyses of Immunome, Inc. (IMNM) stock news and press releases, with sentiment and confidence scoring updated continuously.
Immunome Reports Second Quarter 2026 Financial Results and Pipeline Progress
BullishEarnings ReleaseUpcoming regulatory milestones and clinical data readouts across pipeline assets, including varegacestat PDUFA date in April 2027. (Timing: Throughout 2026 and 2027)Aug 11, 2026Immunome Doses First Patient in Phase 1 Trial for Potential First-in-Class ADC IM-1617
BullishClinical ResultsThe specific event is the dosing of the first patient in the Phase 1 trial for IM-1617, a potential first-in-class antibody-drug conjugate designed to treat advanced solid tumors. (Timing: Initial safety and dose-escalation data from Phase 1 trials typically become available within 1-2 years, with additional updates as the trial progresses.)Jun 11, 2026Immunome Reports Q1 2026 Results with Key Pipeline Progress
BullishEarnings ReleaseFurther regulatory decisions for varegacestat following the NDA submission, additional clinical trial data readouts for other pipeline assets, and progress on new INDs for preclinical programs. (Timing: Throughout 2026 and into 2028, with potential FDA decision for varegacestat, ASCO presentation, and further trial initiations.)May 12, 2026Immunome to Present Phase 3 RINGSIDE Data at 2026 ASCO Annual Meeting
BullishOral presentation of Phase 3 RINGSIDE trial data for varegacestat at the ASCO Annual Meeting, potentially validating prior positive results and increasing market confidence. (Timing: May 30, 2026)Apr 21, 2026
Want the full picture?
These are AI analyses of recent press releases. Sign up to see full reasoning, confidence details, and get real-time alerts.
Sign Up for FreeFrequently Asked Questions
Is Immunome, Inc. (IMNM) bullish or bearish right now?
AI Sentiment on IMNM: 4 Bullish.
What was the latest AI analysis for Immunome, Inc. (IMNM)?
The latest analysis was published on 8/11/2026 with the headline: "Immunome Reports Second Quarter 2026 Financial Results and Pipeline Progress".
How does Bekodia analyze Immunome, Inc. (IMNM) stock?
Bekodia uses advanced AI models to process Immunome, Inc. (IMNM) press releases and news in real-time, extracting sentiment, confidence scores, and key catalysts while filtering out market noise.